Document is current
Any future updates will be listed below
-
Authors
Flethøj, Mette https://orcid.org/0000-0002-2075-1229
Debes, Karina Poulsdóttir https://orcid.org/0009-0000-1325-3582
Larsen, Cecilie
de Blanck, Caroline
Ludvigsen, Trine Pagh
Kirchhoff, Jeppe
Møller, Jacob Eifer
Larsen, Steen
Gøtze, Jens P.
Jespersen, Thomas
Olsen, Lisbeth Høier https://orcid.org/0000-0002-0292-3111
-
Funding
Funding for this research was provided by:
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Innovationsfonden (9066-00032B)
Novo Nordisk A/S and the Novo Nordisk In Vivo Pharmacology LifePharm Centre at University of Copenhagen
- License Information
-
More Information
Article History
Received: 5 January 2024
Accepted: 25 February 2025
First Online: 27 March 2025
Competing interests
: M.F., K.P.D. and T.P.L. are minor stakeholders of Novo Nordisk A/S shares. The other authors declare no competing interests.
